<DOC>
	<DOCNO>NCT00518362</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Tripterygium ( TW ) versus Valsartan ( ARB ) Diabetic Nephropathy ( DN ) .</brief_summary>
	<brief_title>To Compare Efficacy Safety Tripterygium ( TW ) Versus Valsartan Diabetic Nephropathy ( DN )</brief_title>
	<detailed_description>Diabetic nephropathy heavy proteinuria high risk progress end stage renal disease . Though recent study show ACEI ARB could reduce proteinuria DN slow progression ESRD . But ARBs reduce proteinuria 30 % , patient still heavy proteinuria , loss renal function rapidly . So , reduce proteinuria DN important therapy target . Tripterygium ( TW ) Chinese traditional patent drug , reduce proteinuria chronic glomerular nephritis . So , design randomize , prospective clinical trial ass efficacy safety TW versus ARB treatment heavy proteinuria DN .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . A new diagnosis diabetic nephropathy prove histology ( ) serology . 2 . Proteinuria &gt; 2.5 g/24 h 3. serum creatinine &lt; 3 mg/dl 4. age 3565 year 1 . Coexistence anther chronic glomerular nephritis . 2 . Severe disfunction liver 3 . White blood cell &lt; 3000/ul 4 . Severe infection past 1 month 5 . Malignant hypertension hard control 6 . Myocardial infarct heart failure sever cerebral vessel complication past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>TW</keyword>
	<keyword>Valsartan</keyword>
	<keyword>treatment</keyword>
	<keyword>diabetic nephropathy</keyword>
	<keyword>Proteinuria</keyword>
</DOC>